Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic triple-negative breast cancer compared with chemotherapy, according to results from a ...

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

Aprepitant is associated with improved survival outcomes in early-stage breast cancer, particularly in triple-negative cases, showing significant DDFS and BCSS improvements. The study analyzed 13,811 ...

March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...

A research trial spearheaded by Merck hopes to change that — and Franciscan Health Indianapolis is at the forefront too, as it is the only hospital in Indiana selected to take part in the ...

CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

Shortly after her 50th birthday, Shewanna Strickland's routine mammogram revealed a troubling spot on her breast.

One Charlotte cancer survivor who is hoping sharing her story online will inspire others to be proactive and listen to their ...